A study published in The Journal of the National Cancer Institute, found that advanced chemotherapy put patients at far greater
risks of harm than adverse effect reports from clinical trial data reveal.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
USA Today reports that last year the pharmaceutical industry "faced the most product liability lawsuits of any other industry."
An editorial in today's New York Times is a follow-up to its riveting report by Ian Urbina on the recommendation by an Institute of Medicine panel to
lift 1978 federal restrictions on medical experiments on prisoners. http://www.nytimes.com/2006/08/13/us/13inmates.html?
The New York Times reports (below) that after months of foot dragging, the FDA has finally issued additional warnings on the labels of widely
prescribed psychostimulant drugs–Ritalin, Adderall, Concerta.
AHRP applauds Ms. Stayorn for taking action after gathering data–and standing up to the pharmaceutical industry driven-psychotropic drug prescribing practice that is destroying children’s brains.
The verdict is th fourth multi-million dollar loss for Merck in Vioxx litigation.
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
Recently, MSNBC’s Joe Scarborough revisited a shocking investigative news report by New York Times reporters, WALT BOGDANICH AND ERIC KOLI, published May 22, 2003.
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
"Even though clinical research is a noble and worthy activity, it’s very easy to lose your moral compass if your primary goal is the dollar amount of grant funding that you generate."
